Anika Therapeutics, Inc.

DB:AKP Stock Report

Market Cap: €240.4m

Anika Therapeutics Management

Management criteria checks 3/4

Anika Therapeutics' CEO is Cheryl Blanchard, appointed in Feb 2020, has a tenure of 4.75 years. total yearly compensation is $4.46M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 1.2% of the company’s shares, worth €2.88M. The average tenure of the management team and the board of directors is 3 years and 4.2 years respectively.

Key information

Cheryl Blanchard

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage16.3%
CEO tenure4.8yrs
CEO ownership1.2%
Management average tenure3yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cheryl Blanchard's remuneration changed compared to Anika Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$74m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$4mUS$726k

-US$83m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$6mUS$695k

-US$15m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$4mUS$668k

US$4m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$10mUS$548k

-US$24m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

US$11m

Mar 31 2020n/an/a

US$28m

Dec 31 2019US$187kn/a

US$27m

Sep 30 2019n/an/a

US$31m

Jun 30 2019n/an/a

US$29m

Mar 31 2019n/an/a

US$30m

Dec 31 2018US$167kn/a

US$19m

Compensation vs Market: Cheryl's total compensation ($USD4.46M) is above average for companies of similar size in the German market ($USD786.80K).

Compensation vs Earnings: Cheryl's compensation has been consistent with company performance over the past year.

CEO

Cheryl Blanchard (60 yo)

4.8yrs

Tenure

US$4,459,800

Compensation

Dr. Cheryl Renee Blanchard, Ph. D. is Director of Elute, Inc. from May 2013. She serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director o...

Leadership Team

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President4.8yrsUS$4.46m1.2%
€ 2.9m
Anne Nunes
Senior VP & COO3.2yrsUS$1.01m0.092%
€ 221.3k
David Colleran
Executive VP4.7yrsUS$1.55m0.23%
€ 541.7k
Michael Levitz
Executive Officerless than a yearUS$1.65m0.32%
€ 770.9k
Stephen Griffin
Executive VPless than a yearno datano data
Ian McLeod
VP & Chief Accounting Officerno datano datano data
Mark Namaroff
Vice President of Investor Relationsno datano datano data
James Chase
Senior Vice President of International Sales & Marketing4.5yrsno datano data
Ben Joseph
Vice President of Commercial & Corporate Development2.8yrsno datano data
Lisa Funiciello
Vice President of Human Resources2.8yrsno datano data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Management: AKP's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President6.3yrsUS$4.46m1.2%
€ 2.9m
William Jellison
Independent Directorless than a yearno data0.018%
€ 44.3k
John Henneman
Independent Chair of the Board5.3yrsUS$249.81k0.20%
€ 491.5k
Susan L. Vogt
Independent Director6.1yrsUS$248.98k0.21%
€ 497.1k
Sheryl Conley
Independent Director3.1yrsUS$242.48k0.14%
€ 326.8k
Glenn Larsen
Independent Director9.8yrsUS$237.48k0.21%
€ 497.8k
Joseph Capper
Independent Directorless than a yearno datano data
Gary Fischetti
Independent Director1.6yrsUS$571.00k0.089%
€ 215.2k
Stephen Richard
Independent Director4.2yrsUS$248.98k0.19%
€ 458.6k

4.2yrs

Average Tenure

63yo

Average Age

Experienced Board: AKP's board of directors are considered experienced (4.2 years average tenure).